CervoMed Inc.
CRVO
$2.89
-$0.02-0.69%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/8/2026
-
TipRanks
5/18/2026
-
TipRanks Financial Blog
5/18/2026
-
Seeking Alpha - Healthcare
5/18/2026
-
SeekingAlpha.com: All News
5/18/2026
-
Globe Newswire
5/18/2026
-
TipRanks Financial Blog
5/17/2026
-
The Cerbat Gem
5/14/2026
-
Zacks Investment Research
5/14/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/5/2026
-
Zacks Investment Research
5/5/2026
-
Zacks Investment Research
4/23/2026
-
TipRanks Financial Blog
4/22/2026
-
TipRanks Financial Blog
4/22/2026
-
TipRanks Financial Blog
4/22/2026
-
Globe Newswire
4/8/2026
-
GuruFocus
4/8/2026
-
Ticker Report
4/7/2026
-
Globe Newswire
4/6/2026
-
TipRanks Financial Blog
4/6/2026
-
TipRanks Financial Blog
4/6/2026
-
TipRanks Financial Blog
4/6/2026
-
TipRanks Financial Blog
4/6/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, May 15, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 744 4400
Address
20 Park Plaza
Boston, MA 02116
Boston, MA 02116
Country
Year Founded
Business Description
Sector
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod...
more